A TRIAL OF INDIVIDUAL DOSE INTENSITY AND RELATIVE PERFORMANCE-FACTORS IN TEGAFUR MAINTENANCE CHEMOTHERAPY FOR HEAD AND NECK-CANCER

被引：0
|
作者：
SAWAKI, S
WATANABE, H
SHIN, T
KUBOTA, T
KOMIYAMA, S
UMEZAKI, T
NAHM, I
机构：
[1] SAGA MED SCH,DEPT OTOLARNYGOL HEAD & NECK SURG,SAGA 849,JAPAN
[2] YOKOHAMA CITY UNIV,SCH MED,DEPT OTOLARYNGOL,YOKOHAMA 236,JAPAN
[3] SHOWA UNIV,FUJIGAOKA HOSP,DEPT OTOLARYNGOL,YOKOHAMA 227,JAPAN
[4] KYUSHU UNIV,FAC MED,DEPT OTOLARYNGOL,FUKUOKA 812,JAPAN
来源：
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY | 1993年 / 250卷 / 07期
关键词：
HEAD AND NECK CANCER; CHEMOTHERAPY; INDIVIDUAL DOSE INTENSITY; RELATIVES PERFORMANCE;
D O I：
暂无
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Tegafur (Sunfural-S), as masked compound of a 5-fluorouracil derivative, was administered orally as a maintenance chemotherapeutic agent at a dose of 600 mg/day in 98 cases of head and neck epithelial cancer. The effectiveness of the drug was evaluated by a statistical method involving two formulae: individual dose intensity (IDI) and relative performance (RP). When comparing patients rated above a reference IDI value of 1.0 with those rated below 1.0, it was not possible to predict patient survival or tumor-free rates. In contrast, the value of the RP did show such a correlation. These findings support the effectiveness of Tegafur as a maintenance chemotherapeutic treatment for head and neck cancer patients.
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [41] Relative dose intensity and 1-year psoas muscle index reduction rate as prognostic factors in gastric cancer patients with postoperative adjuvant chemotherapy
    Shohei Fujita
    Shinichi Sakuramoto
    Kazuaki Matsui
    Gen Ebara
    Keiji Nishibeppu
    Shuichiro Oya
    Shiro Fujihata
    Seigi Lee
    Yutaka Miyawaki
    Hirofumi Sugita
    Hiroshi Sato
    Keishi Yamashita
    International Journal of Clinical Oncology, 2023, 28 : 110 - 120
  • [42] Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy
    Makarenko, Serge
    Dranitsaris, George
    Peixoto, Renata D.
    Ruan, Jenny Y.
    Cheung, Winson Y.
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (11): : 394 - 400
  • [43] Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
    Salama, J. K.
    Stenson, K. M.
    Kistner, E. O.
    Mittal, B. B.
    Argiris, A.
    Witt, M. E.
    Rosen, F.
    Brockstein, B. E.
    Cohen, E. E. W.
    Haraf, D. J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1787 - 1794
  • [44] CETUXIMAB RELATIVE DOSE INTENSITY (RDI) IN RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): FIRST OBSERVATIONAL PROSPECTIVE STUDY IN UNSELECTED PATIENTS (DIRECT TRIAL)
    Guigay, J.
    Peyrade, F.
    Petre-Lazar, B.
    Mornex, F.
    Ceruse, P.
    Digue, L.
    Berrier, A.
    Degardin, M.
    Alfonsi, M.
    Artignan, X.
    Cals, L.
    Faivre, S.
    Vuillemin, E.
    Rolland, F.
    Timochenko, A.
    Babin, E.
    Prevost, A.
    Romano, O.
    Chamorey, E.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] PROSPECTIVE TRIAL OF HIGH-DOSE REIRRADIATION USING DAILY IMAGE GUIDANCE WITH INTENSITY-MODULATED RADIOTHERAPY FOR RECURRENT AND SECOND PRIMARY HEAD-AND-NECK CANCER
    Chen, Allen M.
    Farwell, D. Gregory
    Luu, Quang
    Cheng, Suzan
    Donald, Paul J.
    Purdy, James A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (03): : 669 - 676
  • [46] Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer
    Vlacich, Gregory
    Spratt, Daniel E.
    Diaz, Roberto
    Phillips, John G.
    Crass, Jostin
    Li, Chung-I
    Shyr, Yu
    Cmelak, Anthony J.
    RADIOTHERAPY AND ONCOLOGY, 2014, 110 (03) : 435 - 440
  • [47] Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)
    Guigay, J.
    Chamorey, E.
    Ceruse, P.
    Mornex, F.
    Degardin, M.
    Alfonsi, M.
    Digue, L.
    Berrier, A.
    Artignan, X.
    Cals, L.
    Faivre, S.
    Vuillemin, E.
    Rolland, F.
    Timochenko, A.
    Babin, E.
    Seronde-Delmas, A.
    Prevost, A.
    Romano, O.
    Peyrade, F.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Performance and side effect evaluation of sequentially reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC).
    List, M. A.
    Vokes, E. E.
    Cohen, E. W.
    Stenson, K. M.
    Karrison, T.
    Bruce, B. E.
    Witt, M.
    Haraf, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 294S - 294S
  • [49] Immune-related saliva micro-RNA's to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).
    Bonomi, Marcelo Raul
    Ado, Safoa
    Kooshki, Mitra
    Ahmed, Tamjeed
    Sullivan, Christopher
    Waltonen, Joshua
    Triozzi, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Phase I study of induction chemotherapy followed by intensity-modulated radiation therapy (IMRT), accelerated fractionation (AF), simultaneous integrated boost (SIB), and concomitant high dose cisplatin for locally-advanced head and neck cancer (LAHNC)
    Feldman, L. E.
    Agulnik, M.
    Salama, J.
    Ortiz, R.
    Yao, M.
    Pytynia, K.
    Epstein, J. B.
    Reisberg, D.
    Minn, A.
    Mundt, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345